August 19, 2010 by Carol Katarsky
Mistakes as simple — and avoidable — as confusing an IV with a feeding tube regularly injure and kill patients. And industry interests seem content to allow it to continue.
Read the rest of this entry »
July 22, 2010 by Carol Katarsky
Alfred Sapse faces 20 charges of wire and mail fraud for allegedly scamming 134 patients.
Read the rest of this entry »
June 25, 2010 by Carol Katarsky
A new type of brain scan could give doctors their first chance to prove Alzheimer’s diagnoses while patients are alive.
Read the rest of this entry »
May 6, 2010 by Carol Katarsky
More than 20 different problems with manufacturing and quality control processes at a major pharmaceutical plant were outlined in a report just released by the FDA.
Read the rest of this entry »
April 7, 2010 by Carol Katarsky
Largely unnoticed in the run-up to the recent passage of the health reform law, President Obama also has his sights on improving programs focused on disease prevention and general wellness.
Read the rest of this entry »
March 30, 2010 by Carol Katarsky
Several million cardiac patients have been taking pills never approved, or tested for safety, by the FDA.
Read the rest of this entry »
February 23, 2010 by Carol Katarsky
A new report from the Senate Finance Committee highlights a potential conflict of interest within the FDA — and the safety of one of the world’s top-selling medications.
Read the rest of this entry »
January 26, 2010 by Carol Katarsky
The more research that’s done, the more some physicians worry that generic meds do work differently than the brand names they copy.
Read the rest of this entry »
December 1, 2009 by Carol Katarsky
Turns out, doctors aren’t as up-to-date as they think they are on off-label uses of prescriptions — which could lead them to order treatments they wouldn’t otherwise.
Read the rest of this entry »
October 15, 2009 by Carol Katarsky
We may soon have clearer guidelines as to what medical vendors can say when promoting their products via new social media outlets.
Read the rest of this entry »